{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:05:25Z","timestamp":1793725525162,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL146481"],"award-info":[{"award-number":["R01HL146481"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["900453"],"award-info":[{"award-number":["900453"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MicroRNA-150 (miR-150) is conserved between rodents and humans, is significantly downregulated during heart failure (HF), and correlates with patient outcomes. We previously reported that miR-150 is protective during myocardial infarction (MI) in part by decreasing cardiomyocyte (CM) apoptosis and that proapoptotic small proline-rich protein 1a (<jats:italic>Sprr1a<\/jats:italic>) is a direct CM target of miR-150. We also showed that <jats:italic>Sprr1a<\/jats:italic> knockdown in mice improves cardiac dysfunction and fibrosis post-MI and that <jats:italic>Sprr1a<\/jats:italic> is upregulated in pathological mouse cardiac fibroblasts (CFs) from ischemic myocardium. However, the direct functional relationship between miR-150 and SPRR1A during both post-MI remodeling in mice and human CF (HCF) activation was not established. Here, using a novel miR-150 knockout;<jats:italic>Sprr1a<\/jats:italic>-hypomorphic (<jats:italic>Sprr1a<\/jats:italic><jats:sup><jats:italic>hypo\/hypo<\/jats:italic><\/jats:sup>) mouse model, we demonstrate that <jats:italic>Sprr1a<\/jats:italic> knockdown blunts adverse post-MI effects caused by miR-150 loss. Moreover, HCF studies reveal that <jats:italic>SPRR1A<\/jats:italic> is upregulated in hypoxia\/reoxygenation-treated HCFs and is downregulated in HCFs exposed to the cardioprotective \u03b2-blocker carvedilol, which is inversely associated with miR-150 expression. Significantly, we show that the protective roles of miR-150 in HCFs are directly mediated by functional repression of profibrotic <jats:italic>SPRR1A<\/jats:italic>. These findings delineate a pivotal functional interaction between miR-150 and SPRR1A as a novel regulatory mechanism pertinent to CF activation and ischemic HF.<\/jats:p>","DOI":"10.1038\/s41419-023-05982-y","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T06:09:40Z","timestamp":1689746980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["SPRR1A is a key downstream effector of MiR-150 during both maladaptive cardiac remodeling in mice and human cardiac fibroblast activation"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-115X","authenticated-orcid":false,"given":"Satoshi","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Moukette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa N.","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-8562","authenticated-orcid":false,"given":"Taiki","family":"Hayasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Aonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Haskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-8123","authenticated-orcid":false,"given":"Suthat","family":"Liangpunsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoliang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-8337","authenticated-orcid":false,"given":"Il-man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"5982_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2174\/1389557515666150324123913","volume":"15","author":"Z Lei","year":"2015","unstructured":"Lei Z, Sluijter JP, van Mil A. MicroRNA therapeutics for cardiac regeneration. Mini Rev Med Chem. 2015;15:441\u201351.","journal-title":"Mini Rev Med Chem"},{"key":"5982_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/CIRCGENETICS.109.857425","volume":"2","author":"D Catalucci","year":"2009","unstructured":"Catalucci D, Gallo P, Condorelli G. MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet. 2009;2:402\u20138.","journal-title":"Circ Cardiovasc Genet"},{"key":"5982_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCRESAHA.110.227496","volume":"108","author":"E van Rooij","year":"2011","unstructured":"van Rooij E. The art of microRNA research. Circ Res. 2011;108:219\u201334.","journal-title":"Circ Res"},{"key":"5982_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1172\/JCI59327","volume":"122","author":"AB Aurora","year":"2012","unstructured":"Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E, Matsuzaki S, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca(2)(+) overload and cell death. J Clin Investig. 2012;122:1222\u201332.","journal-title":"J Clin Investig"},{"key":"5982_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/FJC.0000000000000178","volume":"65","author":"G Arunachalam","year":"2015","unstructured":"Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol. 2015;65:419\u201329.","journal-title":"J Cardiovasc Pharmacol"},{"key":"5982_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"5982_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omtn.2017.06.005","volume":"8","author":"C Chakraborty","year":"2017","unstructured":"Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132\u201343.","journal-title":"Mol Ther Nucleic Acids"},{"key":"5982_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig New Drugs. 2017;35:180\u20138.","journal-title":"Investig New Drugs"},{"key":"5982_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685\u201394.","journal-title":"N Engl J Med"},{"key":"5982_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J Taubel","year":"2021","unstructured":"Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178\u201388.","journal-title":"Eur Heart J"},{"key":"5982_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCRESAHA.114.302766","volume":"114","author":"IM Kim","year":"2014","unstructured":"Kim IM, Wang Y, Park KM, Tang Y, Teoh JP, Vinson J, et al. Beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing. Circ Res. 2014;114:833\u201344.","journal-title":"Circ Res"},{"key":"5982_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cvr\/cvv121","volume":"106","author":"Y Tang","year":"2015","unstructured":"Tang Y, Wang Y, Park KM, Hu Q, Teoh JP, Broskova Z, et al. MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res. 2015;106:387\u201397.","journal-title":"Cardiovasc Res"},{"key":"5982_CR13","doi-asserted-by":"publisher","first-page":"e150405","DOI":"10.1172\/jci.insight.150405","volume":"6","author":"T Aonuma","year":"2021","unstructured":"Aonuma T, Moukette B, Kawaguchi S, Barupala NP, Sepulveda MN, Corr C, et al. Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A. JCI Insight. 2021;6:e150405.","journal-title":"JCI Insight"},{"key":"5982_CR14","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/jcb.25057","volume":"116","author":"W Liu","year":"2015","unstructured":"Liu W, Liu Y, Zhang Y, Zhu X, Zhang R, Guan L, et al. MicroRNA-150 protects against pressure overload-induced cardiac hypertrophy. J Cell Biochem. 2015;116:2166\u201376.","journal-title":"J Cell Biochem"},{"key":"5982_CR15","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1159\/000445568","volume":"38","author":"P Deng","year":"2016","unstructured":"Deng P, Chen L, Liu Z, Ye P, Wang S, Wu J, et al. MicroRNA-150 inhibits the activation of cardiac fbroblasts by regulating c-Myb. Cell Physiol Biochem. 2016;38:2103\u201322.","journal-title":"Cell Physiol Biochem"},{"key":"5982_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/CIRCGENETICS.113.000077","volume":"6","author":"Y Devaux","year":"2013","unstructured":"Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, et al. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ Cardiovasc Genet. 2013;6:290\u20138.","journal-title":"Circ Cardiovasc Genet"},{"key":"5982_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.healun.2013.10.014","volume":"33","author":"S Kreth","year":"2014","unstructured":"Kreth S, Ledderose C, Schutz S, Beiras A, Heyn J, Weis F, et al. MicroRNA-150 inhibits expression of adiponectin receptor 2 and is a potential therapeutic target in patients with chronic heart failure. J Heart Lung Transpl. 2014;33:252\u201360.","journal-title":"J Heart Lung Transpl"},{"key":"5982_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1164\/rccm.201205-0839OC","volume":"187","author":"CJ Rhodes","year":"2013","unstructured":"Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;187:294\u2013302.","journal-title":"Am J Respir Crit Care Med"},{"key":"5982_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.amjcard.2013.11.060","volume":"113","author":"Y Goren","year":"2014","unstructured":"Goren Y, Meiri E, Hogan C, Mitchell H, Lebanony D, Salman N, et al. Relation of reduced expression of miR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. 2014;113:976\u201381.","journal-title":"Am J Cardiol"},{"key":"5982_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1161\/CIRCGENETICS.114.000598","volume":"8","author":"Z Liu","year":"2015","unstructured":"Liu Z, Ye P, Wang S, Wu J, Sun Y, Zhang A, et al. MicroRNA-150 protects the heart from injury by inhibiting monocyte accumulation in a mouse model of acute myocardial infarction. Circ Cardiovasc Genet. 2015;8:11\u201320.","journal-title":"Circ Cardiovasc Genet"},{"key":"5982_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.healun.2017.02.008","volume":"36","author":"D Scrutinio","year":"2017","unstructured":"Scrutinio D, Conserva F, Passantino A, Iacoviello M, Lagioia R, Gesualdo L. Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective study. J Heart Lung Transplant. 2017;36:616\u201324.","journal-title":"J Heart Lung Transplant"},{"key":"5982_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF02738069","volume":"30","author":"J Tesfaigzi","year":"1999","unstructured":"Tesfaigzi J, Carlson DM. Expression, regulation, and function of the SPR family of proteins. a review. Cell Biochem Biophys. 1999;30:243\u201365.","journal-title":"Cell Biochem Biophys"},{"key":"5982_CR23","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/sj.emboj.7600454","volume":"23","author":"S Pradervand","year":"2004","unstructured":"Pradervand S, Yasukawa H, Muller OG, Kjekshus H, Nakamura T, St Amand TR, et al. Small proline-rich protein 1A is a gp130 pathway- and stress-inducible cardioprotective protein. EMBO J. 2004;23:4517\u201325.","journal-title":"EMBO J"},{"key":"5982_CR24","doi-asserted-by":"publisher","first-page":"112210","DOI":"10.1016\/j.jep.2019.112210","volume":"246","author":"P Wu","year":"2019","unstructured":"Wu P, Zhang Z, Ma G, Li J, Zhou W. Transcriptomics and metabolomics reveal the cardioprotective effect of Compound Danshen tablet on isoproterenol-induced myocardial injury in high-fat-diet fed mice. J Ethnopharmacol. 2019;246:112210.","journal-title":"J Ethnopharmacol"},{"key":"5982_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/dna.2018.4551","volume":"38","author":"M Su","year":"2019","unstructured":"Su M, Hu X, Lin J, Zhang L, Sun W, Zhang J, et al. Identification of candidate genes involved in renal ischemia\/reperfusion injury. DNA Cell Biol. 2019;38:256\u201362.","journal-title":"DNA Cell Biol"},{"key":"5982_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0378-1119(98)00507-1","volume":"224","author":"SP Reddy","year":"1998","unstructured":"Reddy SP, Konkin T, Wu R. Structure and organization of the genes encoding mouse small proline-rich proteins, mSPRR1A and 1B. Gene. 1998;224:59\u201366.","journal-title":"Gene."},{"key":"5982_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1021\/acs.jproteome.1c00098","volume":"20","author":"H Shah","year":"2021","unstructured":"Shah H, Hacker A, Langburt D, Dewar M, McFadden MJ, Zhang H, et al. Myocardial infarction induces cardiac fibroblast transformation within injured and noninjured regions of the mouse heart. J Proteome Res. 2021;20:2867\u201381.","journal-title":"J Proteome Res"},{"key":"5982_CR28","doi-asserted-by":"publisher","first-page":"e008686","DOI":"10.1161\/CIRCHEARTFAILURE.121.008686","volume":"15","author":"T Aonuma","year":"2022","unstructured":"Aonuma T, Moukette B, Kawaguchi S, Barupala NP, Sepulveda MN, Frick K, et al. MiR-150 attenuates maladaptive cardiac remodeling mediated by long noncoding RNA MIAT and directly represses profibrotic Hoxa4. Circ Heart Fail. 2022;15:e008686.","journal-title":"Circ Heart Fail"},{"key":"5982_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10557-011-6289-5","volume":"25","author":"VK Topkara","year":"2011","unstructured":"Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther. 2011;25:171\u201382.","journal-title":"Cardiovasc Drugs Ther"},{"key":"5982_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.yexcr.2012.11.015","volume":"319","author":"Y Duan","year":"2013","unstructured":"Duan Y, Zhou B, Su H, Liu Y, Du C. MiR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp Cell Res. 2013;319:173\u201384.","journal-title":"Exp Cell Res"},{"key":"5982_CR31","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1172\/JCI31901","volume":"117","author":"T Noma","year":"2007","unstructured":"Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Investig. 2007;117:2445\u201358.","journal-title":"J Clin Investig"},{"key":"5982_CR32","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41420-022-01295-9","volume":"8","author":"B Moukette","year":"2022","unstructured":"Moukette B, Kawaguchi S, Sepulveda MN, Hayasaka T, Aonuma T, Liangpunsakul S, et al. MiR-150 blunts cardiac dysfunction in mice with cardiomyocyte loss of beta(1)-adrenergic receptor\/beta-arrestin signaling and controls a unique transcriptome. Cell Death Discov. 2022;8:504.","journal-title":"Cell Death Discov"},{"key":"5982_CR33","first-page":"112","volume":"10","author":"P Davoodian","year":"2017","unstructured":"Davoodian P, Ravanshad M, Hosseini SY, Khanizadeh S, Almasian M, Nejati Zadeh A, et al. Effect of TGF-beta\/smad signaling pathway blocking on expression profiles of miR-335, miR-150, miR-194, miR-27a, and miR-199a of hepatic stellate cells (HSCs). Gastroenterol Hepatol Bed Bench. 2017;10:112\u20137.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"5982_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/ijmm.2013.1356","volume":"32","author":"J Zheng","year":"2013","unstructured":"Zheng J, Lin Z, Dong P, Lu Z, Gao S, Chen X, et al. Activation of hepatic stellate cells is suppressed by microRNA-150. Int J Mol Med. 2013;32:17\u201324.","journal-title":"Int J Mol Med"},{"key":"5982_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1165\/rcmb.2007-0401OC","volume":"41","author":"L Zheng","year":"2009","unstructured":"Zheng L, Zhou Z, Lin L, Alber S, Watkins S, Kaminski N, et al. Carbon monoxide modulates alpha-smooth muscle actin and small proline rich-1a expression in fibrosis. Am J Respir Cell Mol Biol. 2009;41:85\u201392.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5982_CR36","doi-asserted-by":"publisher","first-page":"115156","DOI":"10.1016\/j.jep.2022.115156","volume":"291","author":"Y Gu","year":"2022","unstructured":"Gu Y, Zhang S, Chen X, Li Y, Liu Y. LongShengZhi alleviated cardiac remodeling via upregulation microRNA-150-5p with matrix metalloproteinase 14 as the target. J Ethnopharmacol. 2022;291:115156.","journal-title":"J Ethnopharmacol"},{"key":"5982_CR37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1006\/bbrc.1995.1533","volume":"209","author":"N Iwai","year":"1995","unstructured":"Iwai N, Shimoike H, Kinoshita M. Genes up-regulated in hypertrophied ventricle. Biochem Biophys Res Commun. 1995;209:527\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"5982_CR38","doi-asserted-by":"publisher","first-page":"21291","DOI":"10.1074\/jbc.274.30.21291","volume":"274","author":"K Small","year":"1999","unstructured":"Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, et al. Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation. J Biol Chem. 1999;274:21291\u20136.","journal-title":"J Biol Chem"},{"key":"5982_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/sj.cdd.4400267","volume":"4","author":"L Piredda","year":"1997","unstructured":"Piredda L, Amendola A, Colizzi V, Davies PJ, Farrace MG, Fraziano M, et al. Lack of 'tissue' transglutaminase protein cross-linking leads to leakage of macromolecules from dying cells: relationship to development of autoimmunity in MRLIpr\/Ipr mice. Cell Death Differ. 1997;4:463\u201372.","journal-title":"Cell Death Differ"},{"key":"5982_CR40","doi-asserted-by":"publisher","first-page":"20673","DOI":"10.1074\/jbc.M010846200","volume":"276","author":"N Nanda","year":"2001","unstructured":"Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. Targeted inactivation of Gh\/tissue transglutaminase II. J Biol Chem. 2001;276:20673\u20138.","journal-title":"J Biol Chem"},{"key":"5982_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-333","volume":"14","author":"H Zhang","year":"2014","unstructured":"Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.","journal-title":"BMC Cancer"},{"key":"5982_CR42","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s13277-014-2879-8","volume":"36","author":"G Chen","year":"2015","unstructured":"Chen G, Li G, Luo M, Wei X, Wang D, Zhang H, et al. Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer. Tumour Biol. 2015;36:2601\u20135.","journal-title":"Tumour Biol"},{"key":"5982_CR43","first-page":"3417","volume":"19","author":"Y Deng","year":"2020","unstructured":"Deng Y, Zheng X, Zhang Y, Xu M, Ye C, Lin M, et al. High SPRR1A expression is associated with poor survival in patients with colon cancer. Oncol Lett. 2020;19:3417\u201324.","journal-title":"Oncol Lett"},{"key":"5982_CR44","first-page":"3631","volume":"47","author":"J Zhao","year":"2019","unstructured":"Zhao J, Wu C. MiR-463-3p inhibits tibial nerve regeneration via post-transcriptional suppression of SPRR1A artificial cells. Nanomed Biotechnol. 2019;47:3631\u20137.","journal-title":"Nanomed Biotechnol"},{"key":"5982_CR45","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.1523\/JNEUROSCI.0735-16.2016","volume":"36","author":"AD Gaudet","year":"2016","unstructured":"Gaudet AD, Mandrekar-Colucci S, Hall JC, Sweet DR, Schmitt PJ, Xu X, et al. miR-155 deletion in mice overcomes neuron-intrinsic and neuron-extrinsic barriers to spinal cord repair. J Neurosci. 2016;36:8516\u201332.","journal-title":"J Neurosci"},{"key":"5982_CR46","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1523\/JNEUROSCI.22-04-01303.2002","volume":"22","author":"IE Bonilla","year":"2002","unstructured":"Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci. 2002;22:1303\u201315.","journal-title":"J Neurosci"},{"key":"5982_CR47","doi-asserted-by":"publisher","first-page":"e44906","DOI":"10.1371\/journal.pone.0044906","volume":"7","author":"Z Liu","year":"2012","unstructured":"Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS ONE. 2012;7:e44906.","journal-title":"PLoS ONE"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05982-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:04:33Z","timestamp":1689750273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-05982-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["5982"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-05982-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}